Inokuchi K, Inoue T, Tojo A, Futaki M, Miyake K, Yamada T, Tanabe Y, Ohki I, Dan K, Ozawa K
Third Department of Internal Medicine, Nippon Medical School, Japan.
Blood. 1991 Dec 15;78(12):3125-7.
The Philadelphia (Ph1) chromosome, in which the hybrid bcr-abl gene is formed, is thought to be the initial event in chronic myelogenous leukemia (CML). The position of the breakpoint within the breakpoint cluster region (bcr) on Ph1 chromosome and the splicing pattern determine the species of the fused bcr-abl messenger RNA (mRNA). We tried to detect the two types of fused mRNAs in 57 chronic-phase cases of Ph1-positive CML using the polymerase chain reaction procedure (RT-PCR). The bcr exon 2/abl exon 2 fused mRNA (b2-a2) was detected in 17 patients, the bcr exon 3/abl exon 2 fused mRNA (b3-a2) was detected in 34 patients, and both types of mRNA were detected in six patients. The platelet counts of patients who expressed b3-a2 mRNA or both types were significantly higher than those of patients who expressed only b2-a2 (841.5 v 373.5 x 10(9)/L; P less than .015), although there was no significant difference in the white blood cell counts or hemoglobin. This finding suggests a possibility that the type of bcr-abl mRNA may affect the thrombopoietic activity in CML.
费城（Ph1）染色体中形成的杂种bcr-abl基因被认为是慢性粒细胞白血病（CML）的起始事件。Ph1染色体上断裂点簇区域（bcr）内的断裂点位置和剪接模式决定了融合的bcr-abl信使核糖核酸（mRNA）的种类。我们尝试使用聚合酶链反应程序（RT-PCR）在57例Ph1阳性CML慢性期病例中检测两种类型的融合mRNA。在17例患者中检测到bcr外显子2/abl外显子2融合mRNA（b2-a2），在34例患者中检测到bcr外显子3/abl外显子2融合mRNA（b3-a2），在6例患者中检测到两种类型的mRNA。表达b3-a2 mRNA或两种类型mRNA的患者的血小板计数显著高于仅表达b2-a2的患者（841.5对373.5×10⁹/L；P<0.015），尽管白细胞计数或血红蛋白无显著差异。这一发现提示bcr-abl mRNA的类型可能影响CML中的血小板生成活性。
